Massachusetts, US-based clinical-stage biopharmaceutical firm Zenas BioPharma has closed an upsized $200-million Series C round of financing to advance mid- and late-stage immunology-focused clinical development programmes.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
